Beth Weinman Presents on Considerations in Shift Toward U.S. Pharmaceutical Manufacturing

Life Sciences Regulatory & Compliance Counsel Beth Weinman will present in a Fierce Pharma webinar on March 30 on “The Shift Toward U.S. Pharmaceutical Manufacturing: Considerations in Attaining the Right Global Mix.”

The COVID-19 pandemic brought the global interdependency of pharmaceutical supply chains into focus, exposed weaknesses and prompted discussions about the value of reshoring production and facilities manufacturing active pharmaceutical ingredients.

The webinar will focus on topics including:

• Drivers to consider including current legislative action, the scope of onshoring and how to support cost structures
• Balancing cost considerations with other factors including production volume, dosage form, regulatory considerations, and the geography in which the product will launch
• Dual sourcing to mitigate risk
• Building robust supply chains with the capacity to handle disruption
• Supplier qualification
• Lessons learned and best practices to create resilient supply chains